How the 510(k) Submission Process Works: A Step-by-Step Guide for Medical Device Companies

The 510(k) is the most common path to FDA market authorization for medical devices in the United States. Several thousand 510(k)s are submitted to the FDA each year, and the pathway covers the majority of Class II devices: diagnostic imaging equipment, monitoring systems, infusion pumps, wound care products, reusable surgical instruments, software as a medical device (SaMD), and hundreds of other categories.

Understanding how the process works matters for both your regulatory team and your marketing team. The timeline informs your launch plan. The clearance letter defines the exact intended use you can legally market. And knowing the difference between clearance and approval prevents the most common compliance error device companies make in their promotional materials.

This article explains each phase of the 510(k) process, what the FDA reviews, and what clearance actually gives you from a marketing standpoint.

What Is a 510(k) and Why Does It Exist?

The 510(k) takes its name from Section 510(k) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360(k), https://www.law.cornell.edu/uscode/text/21/360). The statute requires device manufacturers to notify the FDA at least 90 days before marketing a device, giving the agency time to determine whether the device requires premarket approval (PMA) or can reach the market via the substantial equivalence pathway.

The premise of the 510(k) is comparative, not absolute. The FDA does not independently evaluate whether your device is safe and effective in an absolute sense. It evaluates whether your device is as safe and effective as a legally marketed predicate device. If the agency finds substantial equivalence, it issues a clearance order. If it cannot, the device is either reclassified, routed to the De Novo process, or required to submit a PMA.

The regulatory framework for 510(k) premarket notifications lives primarily in 21 CFR Part 807, Subpart E (https://www.law.cornell.edu/cfr/text/21/part-807/subpart-E). The FDA also publishes a dedicated 510(k) program page (https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k) that collects current guidance, program databases, and the list of accepted guidance documents.

The Three Types of 510(k)

Not every 510(k) looks the same. The FDA recognizes three submission types, each suited to different circumstances.

Traditional 510(k). The standard pathway. Used for most new devices. Requires a full submission package including device description, intended use, substantial equivalence comparison, performance testing, labeling, and any applicable special controls documentation.

Abbreviated 510(k). Available when the FDA has published a recognized standard or special controls guidance document covering the device type. An abbreviated submission relies on conformance with those standards rather than building the entire technical argument from scratch. The FDA describes the abbreviated pathway at https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/abbreviated-510k.

Special 510(k). Used for modifications to a manufacturer's own previously cleared device. The modification must not affect the intended use or alter the fundamental scientific technology. A special 510(k) focuses on the design control process used to evaluate the change rather than a full predicate comparison. FDA guidance is at https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/special-510k.

Choosing the right type early saves time. Many submissions that start as traditional 510(k)s could have been abbreviated, and submitting an incomplete traditional when an abbreviated would have sufficed adds review time.

What Goes Into a 510(k) Submission

The FDA's content requirements for traditional 510(k) submissions are described in 21 CFR 807.87 (https://www.law.cornell.edu/cfr/text/21/807.87). A complete package typically includes the following elements.

Device description. A clear, specific description of the device: what it is, how it works, the materials, the components, and any accessories. Accompanying photographs, schematics, or engineering drawings are standard.

Intended use and indications for use. These two terms are related but distinct in FDA terminology. Intended use is broader: what the device does and the patient population it serves. Indications for use is more specific: the conditions, diseases, or patient characteristics the device is indicated to diagnose, treat, prevent, or mitigate. The indications for use statement in the 510(k) becomes the foundation of your cleared labeling, and therefore the boundary of your marketing claims.

Predicate identification. A 510(k) must identify at least one predicate device: a legally marketed device to which substantial equivalence is being claimed. The predicate must have the same intended use and the same, or different but not affecting safety or effectiveness, technological characteristics as the new device. The FDA's 510(k) database (https://www.fda.gov/medical-devices/510k-clearances/search-510k) is the primary source for locating cleared predicates.

Substantial equivalence comparison. A structured comparison of the new device to the predicate across intended use and technological characteristics. This is the core technical argument of the submission. If the technological characteristics differ, the submission must include data demonstrating that the differences do not raise new questions of safety and effectiveness.

Performance testing and data. Bench testing, biocompatibility data (ISO 10993 series, as appropriate), electrical safety testing (IEC 60601 series, as applicable), software documentation (FDA's Software as a Medical Device guidance applies to SaMD), sterility and sterilization validation data for devices provided sterile, and clinical data if bench and animal data are insufficient to demonstrate substantial equivalence. The FDA's guidance on clinical performance studies for 510(k)s is at https://www.fda.gov/regulatory-information/search-fda-guidance-documents.

Proposed labeling. Draft labeling including the device name, intended use, directions for use, warnings, contraindications, and any performance specifications. Labeling is reviewed for consistency with the claimed indications for use.

Truthful and accurate statement. The submission must include a signed statement from the submitter or authorized representative certifying that the information in the 510(k) is truthful and accurate, as required by 21 CFR 807.87(k) (https://www.law.cornell.edu/cfr/text/21/807.87).

The Review Timeline: What Happens After Submission

The FDA's review process follows a structured sequence. Understanding it helps you build a realistic pre-launch timeline.

Acceptance review (Day 1 to 15). The FDA conducts an initial completeness check within 15 calendar days of receipt. If the submission is missing required elements, the FDA refuses to accept it (RTA) and returns it with a list of deficiencies. RTA letters are common; they add weeks or months to the timeline but are not disqualifying. The criteria for acceptance are described in the FDA's Refuse to Accept Policy for 510(k)s (https://www.fda.gov/regulatory-information/search-fda-guidance-documents).

Substantive review (the 90-day FDA-review-day goal). Once accepted, the submission enters substantive review. An FDA reviewer evaluates the technical content against the substantial equivalence standard. The 90-day figure is FDA's decision goal measured in FDA review days from acceptance; it is not the total elapsed calendar time. Under MDUFA V, FDA's Total Time to Decision goal is 112 calendar days (FY2025 through FY2027), which includes the time a submission spends on hold during Additional Information cycles. The FDA reports performance against these goals in its published performance data (https://www.fda.gov/medical-devices/510k-clearances/510k-database).

Additional information (AI) requests. If the reviewer needs clarification, missing data, or additional performance testing, they issue an AI request. The review clock stops while you respond. AI cycles are the single biggest source of timeline extension. Each round can add weeks or months depending on the complexity of what is requested and how quickly your team can respond.

Substantial equivalence decision. At the end of review, the FDA issues one of three decisions: (1) substantially equivalent (SE), meaning the device is cleared; (2) not substantially equivalent (NSE), meaning the device cannot enter commerce under this 510(k); or (3) an AI request for additional information. An NSE decision can be appealed administratively and, ultimately, to the courts.

Clearance letter. If the decision is SE, the FDA issues a clearance letter that includes the device name, the cleared intended use, any conditions of clearance, and the K-number assigned to the submission. This letter is the document your marketing team needs to have on file.

Total time to decision for standard 510(k)s frequently runs several months when Additional Information cycles are included. FDA's MDUFA V Total Time to Decision goal is 112 calendar days for FY2025 through FY2027, and published FDA performance data is the authoritative source for actual medians. Complex devices, novel technology, and software-heavy submissions tend to run longer.

What Clearance Means for Your Marketing Program

510(k) clearance is marketing authorization for the device as submitted. Three things follow from that.

The cleared indications are the boundary of your claims. Every marketing claim about what the device does, who it benefits, and what conditions it treats must stay within the indications for use as cleared. Going outside those indications in promotional materials can establish a new intended use under FDA's traditional analysis, which can render the device misbranded or require a new 510(k). See our related article on medical device marketing claims and FDA warning letters for the enforcement pattern.

The correct marketing term is "FDA cleared," not "FDA approved." 21 CFR 807.97 (https://www.law.cornell.edu/cfr/text/21/807.97) explicitly states that a substantial equivalence determination "does not in any way denote official approval of the device." The term "FDA approved" is reserved for devices that completed Premarket Approval. See our full explainer on FDA cleared vs FDA approved.

Modifications may require a new 510(k). If you change the device after clearance, the change may or may not require a new submission. The FDA's guidance "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/regulatory-information/search-fda-guidance-documents) describes the decision process. A material change that is not evaluated before marketing can undermine your clearance claims and expose the company to enforcement.

Where the 510(k) Fits in Your Launch Timeline

For planning purposes: FDA's MDUFA V Total Time to Decision goal is 112 calendar days for FY2025 through FY2027, and real submissions frequently run several months longer once Additional Information cycles are included. Devices with novel technological characteristics, software, or a thin predicate landscape take longer still.

For marketing teams, this means launch-readiness content (website copy, sales decks, trade show materials) should be written around the draft indications for use, with a regulatory review gate before any claim about the device goes public. Claims that exceed the cleared indications are as much a compliance issue as using "approved" instead of "cleared."

Buzzbox Media has worked with medical device companies on the marketing side of this timeline for over 15 years. If your team is preparing for a 510(k) clearance and wants to build a marketing program that holds up to regulatory review, a 30-minute call is a reasonable starting point. Book at https://www.buzzboxmedia.com/book.